Citigroup Maintains Neutral on Teladoc Health, Lowers Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Daniel Grosslight has maintained a Neutral rating on Teladoc Health (NYSE:TDOC) and lowered the price target from $29 to $21.
October 23, 2023 | 3:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Citigroup has maintained a Neutral rating on Teladoc Health and lowered the price target from $29 to $21.
The lowering of the price target by Citigroup indicates a potential downside for Teladoc Health's stock in the short term. This could lead to a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100